

Zdenek Skrott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/480532/publications.pdf>

Version: 2024-02-01

11
papers

752
citations

1477746

6
h-index

1473754

9
g-index

13
all docs

13
docs citations

13
times ranked

1298
citing authors

#	ARTICLE	IF	CITATIONS
1	BODIPY-aza-indole derivate complex as a selective fluorescent sensor for autolysosomes detection. <i>Sensors and Actuators B: Chemical</i> , 2022, 351, 130941.	4.0	0
2	Cannabidiolâ€”induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET. <i>Molecular Oncology</i> , 2022, 16, 1541-1554.	2.1	8
3	A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. <i>Cell Death and Disease</i> , 2022, 13, 203.	2.7	6
4	Microthermal-induced subcellular-targeted protein damage in cells on plasmonic nanosilver-modified surfaces evokes a two-phase HSP-p97/VCP response. <i>Nature Communications</i> , 2021, 12, 713.	5.8	6
5	Abstract 1251: Dithiocarb-copper complex, CuET, demonstrates anti-neoplastic activity in mouse model of prostate cancer and prevents recurrence of tumors. , 2021, , .		0
6	Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway. <i>Cells</i> , 2020, 9, 469.	1.8	31
7	Disulfiramâ€™s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase. <i>Oncogene</i> , 2019, 38, 6711-6722.	2.6	72
8	Targeting genotoxic and proteotoxic stressâ€”response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. <i>Prostate</i> , 2019, 79, 352-362.	1.2	23
9	Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. <i>Nature</i> , 2017, 552, 194-199.	13.7	516
10	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 61-70.	2.0	20
11	Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012, 12, 1184-1192.	1.1	69